Kristin Vidwans
Medical · Falls Church, VANPI 1770671919
Payments from drug & device makers
Across 130 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$486
- Lilly USA, LLC$472
- Novo Nordisk$424
- AstraZeneca$325
- Bayer$305
- GSK$208
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,451100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $486 |
| Lilly USA, LLC | 15 | $472 |
| Novo Nordisk | 20 | $424 |
| AstraZeneca | 11 | $325 |
| Bayer | 6 | $305 |
| GSK | 5 | $208 |
| Pfizer | 13 | $204 |
| Novartis | 8 | $187 |
| Amgen | 4 | $178 |
| Astellas Pharma US Inc | 2 | $127 |
| Viiv Healthcare Company | 5 | $120 |
| Exact Sciences | 3 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Boehringer Ingelheim | 2 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Astellas Pharma Global Development | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Watermark Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,451 in reported general payments places this provider in the 80th percentile of 632 medical providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $40,154 |
| TrintellixVortioxetine Hydrobromide | 15 | $12,845 |
| EliquisApixaban | 14 | $8,601 |
| Celecoxib | 29 | $1,423 |
| Bupropion XlBupropion Hcl | 24 | $1,010 |
| Rosuvastatin Calcium | 42 | $693 |
| Atorvastatin Calcium | 47 | $547 |
| Azelastine Hcl | 25 | $492 |
| Metoprolol Succinate | 35 | $438 |
| Famotidine | 29 | $422 |
| Tamsulosin Hcl | 19 | $348 |
| Olmesartan Medoxomil | 12 | $301 |
| Pantoprazole Sodium | 26 | $279 |
| Atenolol | 21 | $277 |
| Levothyroxine Sodium | 19 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $424 | $40,15426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $12,84515 claims |
| PfizerEliquis | $204 | $8,60114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 632 medical providers in Virginia.
Other medical in Falls Church
- Brian LamFalls Church$51K
- Ana MoyaFalls Church$9K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.